Physician profile
Sajal Kumar
NPI 1063487494
$879.72
in general payments reported to CMS, 2019-2025
13 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.70 · 2020: $92.60 · 2021: $92.84 · 2022: $143 · 2023: $190 · 2024: $207 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $266.42 | 2022-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $161.51 | 2020-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $108.58 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $86.43 | 2024-2025 | |
| Glaxosmithkline, LLC. | $82.64 | 2021-2024 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $49.90 | 2023-2024 | Ibsrela |
| Akebia Therapeutics INC | $38.58 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $20.56 | 2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $16.47 | 2022 | |
| Enterra Medical, INC. | $16.35 | 2023 | |
| Novo Nordisk INC | $15.33 | 2024 | Ozempic |
| Amgen INC. | $13.13 | 2021 | |
| Travere Therapeutics, INC. | $3.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajal Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.